Clinical Trial Update: Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 13-valent pneumococcal conjugate vaccine with 23-valent polysaccharide vaccine in adults has completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• 13-valent pneumococcal conjugate vaccine (13-valent pneumococcal conjugate vaccine)
• 23-valent pneumococcal polysaccharide vaccine (Pneumococcal polysaccharide vaccine 23-valent)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2012-09-05